文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

风湿性二尖瓣疾病女性的妊娠结局:妊娠与心脏病登记研究结果

Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease.
PubMed 文献 · Circulation · 2018-01-01

该国际前瞻性登记研究纳入390例未行瓣膜置换的风湿性二尖瓣疾病孕妇,多数来自新兴国家。孕期死亡1例(1.9%),重度二尖瓣狭窄和显著二尖瓣反流患者心衰发生率分别约50%和23%。孕前心功能NYHA>1级是母体心脏事件的独立预测因素。

要点

  • 重度风湿性二尖瓣狭窄孕妇心衰发生率约50%,显著二尖瓣反流者约23%。
  • 孕期死亡率1.9%,死亡见于重度二尖瓣狭窄患者。
  • 孕前NYHA心功能>1级是母体心脏事件的独立预测因素。

核心结论

  • 孕期死亡率虽仅1.9%,但重度风湿性二尖瓣狭窄和显著二尖瓣反流患者心衰发生率高,孕前咨询和考虑瓣膜干预对预防并发症重要。

研究设计与样本

  • 妊娠与心脏病登记(ROPAC)为国际前瞻性登记,连续纳入心脏病孕妇,本研究分析390例无孕前瓣膜置换的风湿性二尖瓣疾病患者。
  • 采用三级模型(患者-中心-国家)分析患者特征与心脏结局的关联。

主要发现

  • 75%患者来自新兴国家;二尖瓣狭窄(伴或不伴反流)273例,孤立性二尖瓣反流117例。
  • 二尖瓣狭窄程度:轻度20.9%,中度39.2%,重度19.8%,其余未分类。
  • 孕期死亡1例(重度二尖瓣狭窄);二尖瓣狭窄患者住院率23.1%,主要因心衰(轻度15.8%,中度23.4%,重度48.1%;P<0.001)。
  • 中度或重度二尖瓣反流患者心衰发生率23.1%;16例孕期干预(14例经皮球囊二尖瓣交界分离术,2例外科瓣膜置换)。
  • 多变量模型中孕前NYHA>1级是母体心脏事件的独立预测因素;产后6个月随访53%,新增3例死亡(重度二尖瓣狭窄1例、中度二尖瓣狭窄1例、中度至重度二尖瓣反流1例)。

关键数值与推荐

  • 二尖瓣狭窄程度分级:轻度20.9%,中度39.2%,重度19.8%(其余未分类)。
  • 二尖瓣狭窄患者住院率23.1%,其中心衰为住院主因:轻度15.8%、中度23.4%、重度48.1%(P<0.001)。
  • 中度或重度二尖瓣反流患者心衰发生率23.1%。
  • 孕期死亡率1.9%;孕前NYHA>1级为母体心脏事件独立预测因素。

临床怎么用

  • 对风湿性二尖瓣疾病孕妇应进行孕前咨询,评估二尖瓣狭窄程度和心功能。
  • 重度二尖瓣狭窄和显著二尖瓣反流患者孕期心衰风险高,需密切监测。
  • 对选择性患者可考虑孕前二尖瓣干预以预防孕期并发症。

局限性

  • 产后6个月随访仅53%,可能低估晚期死亡。
  • 二尖瓣狭窄程度有部分患者未分类。
  • 多数患者来自新兴国家,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac disease is 1 of the major causes of maternal mortality. We studied pregnancy outcomes in women with rheumatic mitral valve disease. METHODS: The Registry of Pregnancy and Cardiac Disease is an international prospective registry, and consecutive pregnant women with cardiac disease were included. Pregnancy outcomes in all women with rheumatic mitral valve disease and no prepregnancy valve replacement is described in the present study (n=390). A maternal cardiac event was defined as cardiac death, arrhythmia requiring treatment, heart failure, thromboembolic event, aortic dissection, endocarditis, acute coronary syndrome, and hospitalization for other cardiac reasons or cardiac intervention. Associations between patient characteristics and cardiac outcomes were checked in a 3-level model (patient-center-country). RESULTS: Most patients came from emerging countries (75%). Mitral stenosis (MS) with or without mitral regurgitation (MR) was present in 273 women, isolated MR in 117. The degree of MS was mild in 20.9%, moderate in 39.2%, severe in 19.8%, and severity not classified in the remainder. Maternal death during pregnancy occurred in 1 patient with severe MS. Hospital admission occurred in 23.1% of the women with MS, and the main reason was heart failure (mild MS 15.8%, moderate 23.4%, severe 48.1%; P<0.001). Heart failure occurred in 23.1% of patients with moderate or severe MR. An intervention during pregnancy was performed in 16 patients, 14 had percutaneous balloon mitral commissurotomy, and 2 had surgical valve replacement (1 for MS, 1 for MR). In multivariable modeling, prepregnancy New York Heart Association class >1 was an independent predictor of maternal cardiac events. Follow-up at 6 months postpartum was available for 53%, and 3 more patients died (1 with severe MS, 1 with moderate MS, 1 with moderate to severe MR). CONCLUSIONS: Although mortality was only 1.9% during pregnancy, ≈50% of the patients with severe rheumatic MS and 23% of those with significant MR developed heart failure during pregnancy. Prepregnancy counseling and considering mitral valve interventions in selected patients are important to prevent these complications.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. van Hagen IM, Thorne SA, Taha N, et al. Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease: Results From the Registry of Pregnancy and Cardiac Disease. Circulation. 2018. PMID: 29459466. doi:10.1161/CIRCULATIONAHA.117.032561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。